- Home
- NEWT vs CCCC Comparison
NEWT vs CCCC Comparison
Compare NEWT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- CCCC
- Stock Information
- Founded
- NEWT 1998
- CCCC 2015
- Country
- NEWT United States
- CCCC United States
- Employees
- NEWT N/A
- CCCC N/A
- Industry
- NEWT Major Banks
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- NEWT Finance
- CCCC Health Care
- Exchange
- NEWT Nasdaq
- CCCC Nasdaq
- Market Cap
- NEWT 294.8M
- CCCC 175.1M
- IPO Year
- NEWT N/A
- CCCC 2020
- Fundamental
- Price
- NEWT $11.53
- CCCC $2.66
- Analyst Decision
- NEWT Hold
- CCCC Buy
- Analyst Count
- NEWT 4
- CCCC 3
- Target Price
- NEWT $13.00
- CCCC $8.00
- AVG Volume (30 Days)
- NEWT 166.7K
- CCCC 1.1M
- Earning Date
- NEWT 11-05-2025
- CCCC 10-30-2025
- Dividend Yield
- NEWT 6.59%
- CCCC N/A
- EPS Growth
- NEWT 21.23
- CCCC N/A
- EPS
- NEWT 2.01
- CCCC N/A
- Revenue
- NEWT $364,004,000.00
- CCCC $34,240,000.00
- Revenue This Year
- NEWT N/A
- CCCC N/A
- Revenue Next Year
- NEWT $12.73
- CCCC N/A
- P/E Ratio
- NEWT $5.73
- CCCC N/A
- Revenue Growth
- NEWT 20.91
- CCCC 16.55
- 52 Week Low
- NEWT $9.12
- CCCC $1.09
- 52 Week High
- NEWT $15.49
- CCCC $7.22
- Technical
- Relative Strength Index (RSI)
- NEWT 40.23
- CCCC 56.55
- Support Level
- NEWT $11.44
- CCCC $2.58
- Resistance Level
- NEWT $11.77
- CCCC $2.75
- Average True Range (ATR)
- NEWT 0.25
- CCCC 0.16
- MACD
- NEWT -0.11
- CCCC -0.01
- Stochastic Oscillator
- NEWT 8.65
- CCCC 63.46
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.